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Neuromyelitis optica (NMO), or Devic’s disease, is
a relapsing demyelinating disease of the central nervous
system characterized by optic neuritis and myelitis with
distinct clinical, imaging, CSF and serological features
(Wingerchuk et al., 2006). There is increasing evidence
that NMO is an antibody-mediated organ-specific auto-
immune disease associated with anti-aquaporin 4 antibodies
detectable in serum (Lennon et al., 2004), supported by
four recent papers in the same edition of Brain (Matsuoka
et al., 2007; Misu et al., 2007; Roemer et al., 2007;
Takahashi et al., 2007) and the accompanying scientific
commentary (Compston, 2007). However, it is still not
known why the disorder specifically targets the optic nerves
and spinal cord. Several siblings with NMO have been
reported (McAlpine, 1938; Keegan and Weinshenker, 2000;
Yamakawa et al., 2000), raising the possibility of a genetic
predisposition, but no pathogenic mutations have been
identified in the AQP4 gene on chromosome 18q11.2-q12.1
(Lu et al., 1996).
NMO has similarities with Leber hereditary optic
neuropathy (LHON, MIM 535 000) which is primarily
due to mutations of mitochondrial DNA (mtDNA) that
disrupt complex I of the respiratory chain (Carelli et al.,
2004). Although the genetic defect in LHON is present in
all tissues, the pathology also is strikingly tissue-specific.
Most affected individuals develop sub-acute painless visual
failure due to focal involvement of both optic nerves
(Newman et al., 1991; Riordan-Eva et al., 1995), but some
also develop a progressive myelopathy, with high signal
extending over multiple spinal levels on MR imaging, and
the absence of oligoclonal bands in the CSF (Johns et al.,
1991; Jaros et al., 2007). Tissue-specific susceptibility to
mitochondrial dysfunction is thought to explain why the
neurodegeneration in LHON only affects specific neuronal
pathways, and recent evidence implicates a similar mecha-
nism in the axonal loss that follows acute inflammatory
lesions in multiple sclerosis (MS) (Dutta et al., 2006).
A further link between LHON and central nervous
system demyelination is the MS-like illness first described
in women harbouring LHON mtDNA mutations (Harding
et al., 1992), characterized by severe and often irreversible
bilateral visual failure. Patients with LHON-MS have typical
brain imaging and unmatched oligoclonal bands in the
cerebrospinal fluid (Riordan-Eva et al., 1995). Although the
majority of cases are female, males have been described
with each of the common LHON mtDNA mutations
(Lees et al., 1964; Flanigan and Johns, 1993; Kellar-Wood
et al., 1994; Olsen et al., 1995; Jansen et al., 1996; Leuzzi
et al., 1997; Horvath et al., 2000; Buhmann et al., 2002).
Given the clinical similarities between NMO and LHON,
previous investigators have looked for specific mtDNA
mutations in a small number of patients with NMO
(Johns et al., 1991; Cock et al., 1997; Kalman and Mandler,
2002; Ghezzi et al., 2004), and others have studied poly-
morphic variation of mtDNA in NMO cases (Cock et al.,
1997; Kalman et al., 1999; Kalman and Mandler, 2002;
Celebisoy et al., 2006). However, the largest case series
only included four patients, so the role of mtDNA in the
etiology of NMO has yet to be resolved. To address this
issue we studied the mtDNA of 32 British patients with
NMO fulfilling recent diagnostic criteria (Wingerchuk et al.,
2006). These patients are part of the United Kingdom
NMO study cohort co-collected through the British Neurol-
ogical Surveillance Unit (Jacob et al., 2005). Two different
hypotheses were tested: (i) that highly deleterious patho-
genic LHON mtDNA mutations are a common cause of
NMO; and, (ii) that mtDNA polymorphisms are associated
with NMO. We consciously limited our study to patients
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of European maternal ancestry to allow interpretation
of the mtDNA genetic background in an appropriate
population context.
Are pathogenic LHON mtDNAmutations
a common cause of NMO?
We sequenced the MTND1, MTND4 and MTND6 genes
which are known to harbour the vast majority (499%) of
LHON mutations, including the three most common:
m.3260G4A, m.11778G4A, and m.14484T4C (Mackey
et al., 1996), and other primary pathogenic mutations
found within the ND6 ‘‘hotspot’’ (Chinnery et al., 2001).
No LHON or other known pathogenic mutations were
identified in the 32 NMO cases.
Are mtDNA polymorphisms associated
with NMO?
There are a number of different ways that polymorphic
variation of mtDNA could be associated with NMO.
Human mtDNA is maternally inherited and has acquired
extensive variation over time. Substitutions acquired
410 000 years before the present subdivide the phylogeny
into a number of discrete clades called haplogroups.
Specific haplogroups are preferentially associated with
mtDNA mutations that cause LHON, and increase the
clinical penetrance of the disorder (Brown et al., 1997; Man
et al., 2004). Sub-haplogroup J1 is associated with an
increased risk of visual failure in m.14484T4C pedigrees,
and J2 is associated with an increased risk of visual failure
in m.11778G4A pedigrees (Carelli et al., 2006; Hudson
et al., 2007).
Epidemiological evidence has led to the suggestion that
NMO is a prototypic form of MS which emerged out
of Africa, and was shaped into its current form through
a gene-environment interaction between Human leukocyte
antigens and Epstein-Barr virus, either through genetic
hitch-hiking or in parallel to the emergence of mtDNA
haplogroup J from Western Asia (Compston, 2004;
Cox et al., 2005). In keeping with this, small studies have
reported an association between optico-spinal MS and
haplogroup J (Mayr-Wohlfart et al., 1996; Reynier et al.,
1999; Kalman and Mandler, 2002), although this has not
been a universal finding (Otaegui et al., 2004).
To determine whether these deep-rooted haplogroup-
defining polymorphisms are associated with NMO, the
mtDNA haplogroup was defined in all 32 NMO cases by
PCR-RFLP analysis (Torroni et al., 1997), and compared to
1010 British controls (part of the 1958 UK-MRC birth
cohort, Table 1). There was no significant difference in the
overall haplogroup distribution (Exact P= 0.117), nor in
the frequency of the individual haplogroups (Table 1).
Direct sequencing of the mtDNA regions encompassing
nucleotides 3010 (3010 in J1) and 15257 (15257A in J2) Ta
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revealed that the one haplogroup J case of NMO belonged
to sub-haplogroup J1c.
Recent phylogenetic analysis and association studies
of extensive LHON pedigrees suggests that substitutions
in the mtDNA gene coding for cytochrome b, MTCYB,
are responsible for the increased risk of visual failure in
haplogroup J m.11778G4A and m.14484T4C pedigrees
(Carelli et al., 2006; Hudson et al., 2007). This may arise
through the interaction between complex I and III (cyt b)
subunits in super-complexes (Schagger and Pfeiffer, 2000),
or the cumulative effect of deleterious mutations affecting
serial components of the respiratory chain. We therefore
sequenced the entire MTCYB gene in the 32 NMO patients
and compared the result to 100 datasets of 32 randomly
selected healthy control subjects identified from a subgroup
of 527 healthy controls within MitoKor database
(Herrnstadt et al., 2002), calculating the number of synon-
ymous, non-synonymous and the total number substitu-
tions in MTCYB (Table 2, Fig. 1). The total number of
MTCYB substitutions in the 32 NMO cases fell within the
range of control values (Fig. 1a). Likewise, the number
of synonymous and non-synonymous MTCYB changes
in the NMO patients fell within the control range
(Fig. 1b and 1c), as did the ratio of synonymous to non-
synonymous substitutions (Fig. 1d), providing evidence
against the hypothesis that the accumulation of deleterious
substitutions predicted to alter cyt b function predisposes
to NMO.
In conclusion, we found no evidence to support the
hypothesis that ancient mtDNA polymorphisms are asso-
ciated with or predispose to NMO. A study of this size
cannot exclude a subtle increased susceptibility, especially if
conferred by rare mtDNA variants in a region not directly
sequenced here. However, this would be very difficult to
demonstrate, given the rarity of NMO and the samples sizes
required to show a convincing association between mtDNA
variants and a complex disease (Samuels et al., 2006).
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Table 2 MTCYB substitutions in 32 cases of neuromyelitis optica
Patient code MtDNA Haplogroup MTCYB substitutions
1 H m.15326A`G
3 H m.15326A`G
4 H m.15326A`G
6 H m.15326A`G
7 H m.15326A`G
14 H m.15326A`G
16 H
17 H m.15326A`G
18 H m.15326A`G
19 H m.15001T`G m.15326A`G
24 H m.15001T`G m.15326A`G
29 H m.15326A`G
72 H m.15326A`G
80 H m.15064A`G m.15326A`G m.15833C`T
86 H m.15326A`G
88 H m.15326A`G
36 I m.14766C`T m.14927A`G m.15043G`A m.15317G`A m.15326A`G m.15758A`G
85 J m.14766C`T m.14798T`C m.15326A`G m.15452C`A
66 K m.14766C`T m.14798T`C m.15326A`G
64 M m.14766C`T m.14783T`C m.14803C`T m.15043G`A m.15301G`A m.15326A`G
33 T m.14766C`T m.14905G`A m.15326A`G m.15452C`A m.15607A`G
52 T m.14766C`T m.14905G`A m.15326A`G m.15452C`A m.15607A`G
56 T m.14766C`T m.14905G`A m.15326A`G m.15452C`A m.15607A`G
5 U m.14766C`T m.15326A`G m.15631A`G m.15721T`C
34 U m.14766C`T m.14793A`G m.15218A`G m.15317G`A m.15326A`G m.15767C`T
59 U m.14766C`T m.15326A`G
70 U m.14766C`T m.15326A`G
75 U m.14766C`T m.14793A`G m.15218A`G m.15326A`G
49 W m.14766C`T m.15326A`G
77 W m.14766C`T m.15326A`G
31 X m.14766C`T m.15326A`G
58 Other m.15326A`G
(relative to the revised Cambridge reference sequence for mtDNA, Andrews et al., 1999).
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